Sei Foundation Explores Major Biotech Acquisition for Blockchain Integration

The Sei Foundation is exploring a bold move into the biotech space, expressing interest in acquiring 23andMe, the well-known genetic testing company that has recently sought Chapter 11 bankruptcy protection.

The Sei Foundation is reportedly exploring a major acquisition in the biotech space, with reports indicating an interest in acquiring 23andMe.

The interest comes as 23andMe, the consumer genetics testing company known for its spit-in-a-tube DNA kits and recent Chapter 11 bankruptcy filing, is seeking a new buyer to complete its financial recovery.

According to a statement posted by the Sei Foundation on X, previously known as Twitter, the goal is to integrate biotech with Web3 technologies.

The foundation envisions a scenario where over 15 million genetic profiles from 23andMe users could be seamlessly transferred and stored within the blockchain ecosystem.

This would empower individuals with ultimate ownership and control over their most personal information in an unprecedented manner.

Highlighting the urgency of such a move, the Sei Foundation expressed concern over the vulnerability of 23andMe’s user data due to the company’s current financial instability.

In contrast, they touted the superior security and resilience of decentralized storage solutions.

Sei is a cryptocurrency that currently boasts a market valuation of around $1 billion and is actively traded on major exchanges like Binance.

The potential acquisition of 23andMe comes at a time when privacy advocates and state attorneys general are advising users to consider withdrawing their genetic data from the platform.

The integration of 23andMe’s vast database of 15 million genetic profiles with Sei’s Layer-1 blockchain is envisioned to create a unique hybrid ecosystem.

This, in turn, would enable users to decide how they wish to share or monetize their own biological information in the Web3 space.